Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-04-10 00:00:00 ET · period of report 2024-04-08 · accession 0001415889-24-010676 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-04-10 | 2024-04-08 | ELVN | Patel Anish | COO | S - Sale | $18.60 | -4,875 | 2,597 | -65% | -$90.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-08 | S | D | 4,331 | $18.50 | 3,141 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $18.19 to $19.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Common Stock | 2024-04-08 | S | D | 544 | $19.40 | 2,597 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $19.245 to $19.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |